8.27
price up icon0.73%   0.06
after-market After Hours: 8.27
loading
Theravance Biopharma Inc stock is traded at $8.27, with a volume of 127.66K. It is up +0.73% in the last 24 hours and up +2.10% over the past month. Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$8.21
Open:
$8.26
24h Volume:
127.66K
Relative Volume:
0.46
Market Cap:
$402.20M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
0.728
EPS:
11.36
Net Cash Flow:
$-9.60M
1W Performance:
-4.39%
1M Performance:
+2.10%
6M Performance:
-12.58%
1Y Performance:
-16.04%
1-Day Range:
Value
$8.139
$8.30
1-Week Range:
Value
$8.139
$8.65
52-Week Range:
Value
$7.44
$11.71

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name
Name
Theravance Biopharma Inc
Name
Phone
650-808-6000
Name
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Name
Employee
99
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
TBPH's Discussions on Twitter

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Date Action Analyst Rating Change
May-23-22 Initiated SVB Leerink Outperform
Nov-05-21 Upgrade JP Morgan Underweight → Neutral
Sep-15-21 Downgrade JP Morgan Overweight → Underweight
Aug-25-21 Downgrade Morgan Stanley Overweight → Underweight
Aug-24-21 Downgrade Cowen Outperform → Market Perform
Oct-14-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-07-20 Initiated JP Morgan Overweight
Jun-15-20 Initiated Morgan Stanley Equal-Weight
May-13-20 Initiated Cowen Outperform
Jan-08-20 Reiterated H.C. Wainwright Buy
Nov-06-19 Upgrade Robert W. Baird Underperform → Neutral
Oct-29-19 Initiated H.C. Wainwright Buy
Mar-29-18 Resumed Piper Jaffray Overweight
Aug-17-17 Initiated Evercore ISI Outperform
Jun-16-17 Initiated Cantor Fitzgerald Overweight
May-11-17 Reiterated Needham Buy
Dec-21-16 Initiated Needham Buy
Nov-03-16 Initiated Piper Jaffray Overweight
Oct-12-16 Downgrade Robert W. Baird Neutral → Underperform
Aug-03-16 Downgrade BofA/Merrill Neutral → Underperform
Jun-20-16 Initiated Guggenheim Buy
Jun-20-16 Reiterated Leerink Partners Outperform
May-12-16 Initiated Leerink Partners Outperform
May-05-16 Downgrade BofA/Merrill Buy → Neutral
Feb-03-15 Upgrade Robert W. Baird Underperform → Neutral
View All

Theravance Biopharma Inc Stock (TBPH) Latest News

pulisher
10:37 AM

Theravance Biopharma (TBPH) Scheduled to Post Earnings on Tuesday - MarketBeat

10:37 AM
pulisher
03:51 AM

Vanguard Group Inc's Strategic Acquisition in Theravance Biophar - GuruFocus.com

03:51 AM
pulisher
Nov 04, 2024

(TBPH) Proactive Strategies - Stock Traders Daily

Nov 04, 2024
pulisher
Oct 26, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by SG Americas Securities LLC - MarketBeat

Oct 26, 2024
pulisher
Oct 24, 2024

When (TBPH) Moves Investors should Listen - Stock Traders Daily

Oct 24, 2024
pulisher
Oct 24, 2024

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 - StockTitan

Oct 24, 2024
pulisher
Oct 23, 2024

Q3 EPS Estimate for Theravance Biopharma Boosted by Analyst - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - Defense World

Oct 23, 2024
pulisher
Oct 22, 2024

What is Zacks Research's Estimate for TBPH Q4 Earnings? - MarketBeat

Oct 22, 2024
pulisher
Oct 20, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by Analysts - MarketBeat

Oct 20, 2024
pulisher
Oct 20, 2024

The Manufacturers Life Insurance Company Decreases Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Oct 20, 2024
pulisher
Oct 19, 2024

Theravance study shows YUPELRI improves COPD lung function By Investing.com - Investing.com Australia

Oct 19, 2024
pulisher
Oct 19, 2024

Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat

Oct 19, 2024
pulisher
Oct 18, 2024

Theravance study shows YUPELRI improves COPD lung function - Investing.com

Oct 18, 2024
pulisher
Oct 18, 2024

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease - StockTitan

Oct 18, 2024
pulisher
Oct 14, 2024

Where are the Opportunities in (TBPH) - Stock Traders Daily

Oct 14, 2024
pulisher
Oct 11, 2024

Dimensional Fund Advisors LP Has $2.80 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Oct 11, 2024
pulisher
Oct 10, 2024

Theravance Biopharma (STU:0TB) Price-to-Operating-Cash-Flow : (As of Oct. 10, 2024) - GuruFocus.com

Oct 10, 2024
pulisher
Oct 07, 2024

Squarepoint Ops LLC Takes $986,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

Bank of Montreal Can Raises Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Holdings Lifted by Marshall Wace LLP - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

(TBPH) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 03, 2024
pulisher
Oct 02, 2024

XTX Topco Ltd Purchases New Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Oct 02, 2024
pulisher
Sep 28, 2024

Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y - MSN

Sep 28, 2024
pulisher
Sep 25, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Rhumbline Advisers Sells 15,095 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Sep 25, 2024
pulisher
Sep 23, 2024

An Analysis of Theravance Biopharma Inc (TBPH)’s Potential Price Growth - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Theravance Biopharma settles patent litigation with Qilu Pharmaceutical - Investing.com

Sep 23, 2024
pulisher
Sep 21, 2024

Baupost Group LLC MA Decreases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Sep 21, 2024
pulisher
Sep 17, 2024

Theravance Biopharma (NASDAQ:TBPH) Given “Buy” Rating at HC Wainwright - Defense World

Sep 17, 2024
pulisher
Sep 16, 2024

H.C. Wainwright maintains Buy rating on Theravance Biopharma shares By Investing.com - Investing.com Canada

Sep 16, 2024
pulisher
Sep 16, 2024

Theravance Biopharma (NASDAQ:TBPH) Earns Buy Rating from HC Wainwright - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Unveiling 4 Analyst Insights On Theravance Biopharma - Benzinga

Sep 16, 2024
pulisher
Sep 11, 2024

How To Trade (TBPH) - Stock Traders Daily

Sep 11, 2024
pulisher
Sep 11, 2024

Leerink Partners gives a Market perform recommendation for Theravance Biopharma Inc (TBPH) - Knox Daily

Sep 11, 2024
pulisher
Sep 10, 2024

Seth Klarman's Complete Exit from Theravance Biopharma Inc - Yahoo Finance

Sep 10, 2024
pulisher
Sep 10, 2024

Theravance Biopharma Outlines Growth Strategy at Investment Conference - TipRanks

Sep 10, 2024
pulisher
Sep 06, 2024

Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation - Yahoo Finance

Sep 06, 2024
pulisher
Sep 04, 2024

Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Sep 04, 2024
pulisher
Sep 02, 2024

Theravance Biopharma Inc (TBPH) receives a Market perform rating from Leerink Partners - Knox Daily

Sep 02, 2024
pulisher
Aug 31, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of “Hold” by Analysts - Defense World

Aug 31, 2024
pulisher
Aug 31, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Target Price from Analysts - MarketBeat

Aug 31, 2024
pulisher
Aug 28, 2024

Q3 2024 EPS Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH) Reduced by Analyst - MarketBeat

Aug 28, 2024
pulisher
Aug 27, 2024

Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 50-Day Moving Average of $8.90 - MarketBeat

Aug 27, 2024
pulisher
Aug 27, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) to Post Q4 2025 Earnings of $0.41 Per Share, Zacks Research Forecasts - Defense World

Aug 27, 2024
pulisher
Aug 27, 2024

Zacks Research Brokers Increase Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat

Aug 27, 2024
pulisher
Aug 27, 2024

Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizentribune

Aug 27, 2024
pulisher
Aug 27, 2024

Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Below Fifty Day Moving Average of $8.90 - Defense World

Aug 27, 2024
pulisher
Aug 22, 2024

TBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024 - MSN

Aug 22, 2024
pulisher
Aug 21, 2024

Leerink Partners Downgrades Theravance Biopharma Inc (TBPH) to a Market perform from an Outperform - Knox Daily

Aug 21, 2024

Theravance Biopharma Inc Stock (TBPH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Theravance Biopharma Inc Stock (TBPH) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
Jul 10 '24
Sale
9.00
4,000
36,000
335,965
Samaha Eli
10% Owner
May 01 '24
Buy
8.75
1,499,124
13,117,335
8,511,350
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
Feb 22 '24
Sale
8.71
1,254
10,922
311,733
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
Nov 21 '23
Sale
10.29
1,378
14,180
331,206
GRAHAM RICHARD A
SVP, RESEARCH & DEVELOPMENT
Nov 14 '23
Sale
10.22
2,482
25,366
346,839
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):